{"id":"95369cfa-8610-516f-bef5-526994dfa374","stable_key":"53d9b98d-e3a0-5416-bc88-adbe42a8cb1b:curcumin-sulfasalazine-exposure","predicate":"increases","statement":"Sulfasalazine AUC increased 2.0-fold at the microdose and 3.2-fold at the therapeutic dose.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"e458e399-4acb-5101-8bd0-c7d2a39144a4","mechanism_event_label":"The human experiment measured more sulfasalazine in blood.","subject":{"id":"0e625439-d093-5d1b-8713-dcfdafcf6811","slug":"curcumin","display_name":"Curcumin","entity_type_key":"small_molecule"},"object":{"id":"b96edac1-7a96-5e80-bb64-205ad0ef0061","slug":"sulfasalazine-plasma-exposure","display_name":"Human sulfasalazine plasma exposure","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"e458e399-4acb-5101-8bd0-c7d2a39144a4","stable_key":"53d9b98d-e3a0-5416-bc88-adbe42a8cb1b:curcumin-sulfasalazine-exposure-event","event_type":"observed_intervention","label":"The human experiment measured more sulfasalazine in blood.","description":"Sulfasalazine AUC increased 2.0-fold at the microdose and 3.2-fold at the therapeutic dose.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"a5eafc6b-a85d-555d-9a24-13748e96218f","slug":"sulfasalazine","display_name":"Sulfasalazine","entity_type_key":"small_molecule"},"role":"coadministered_drug","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"a52e10c2-fd56-564b-8c05-27e9fce27cd6","slug":"abcg2","display_name":"Human ABCG2 / breast cancer resistance protein","entity_type_key":"protein"},"role":"separately_tested_transporter","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"0e625439-d093-5d1b-8713-dcfdafcf6811","slug":"curcumin","display_name":"Curcumin","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"b96edac1-7a96-5e80-bb64-205ad0ef0061","slug":"sulfasalazine-plasma-exposure","display_name":"Human sulfasalazine plasma exposure","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/curcumin-research/22300367.abstract.txt\", \"locator\": \"Primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"a8ec64e7dff4a52838fa067fdc9418ee3ebe768c4a4d53629bd84f9f0ffe67fe\", \"start_char\": 0, \"end_char\": 1713, \"text_sha256\": \"a8ec64e7dff4a52838fa067fdc9418ee3ebe768c4a4d53629bd84f9f0ffe67fe\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Human pharmacokinetics, transporter vesicles and mouse knockout experiment","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Human: curcumin 2 g before sulfasalazine 100 micrograms or 2 g; eight participants. Mouse: 300-400 mg/kg curcumin","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Small dose- and formulation-specific drug study. Transporter inference is supported by separate assays, not a universal effect on every BCRP substrate.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Curcumin research collection; topical membership is not evidence of a direct dietary effect.","comparator":null,"unit":null,"notes":"","entity":{"slug":"curcumin","display_name":"Curcumin","entity_type_key":"small_molecule"}},{"dimension":"organism","value_text":"Human transporter/human participants; mouse claims separately scoped","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"The human experiment measured more sulfasalazine in blood.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[curcumin-p22300367] Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP. (2012). https://pubmed.ncbi.nlm.nih.gov/22300367/ DOI: 10.1111/j.1476-5381.2012.01887.x","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Intestinal drug transport and plasma","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"d43acbcd-01dc-5a98-8235-6130be796a12","evidence_kind":"source_excerpt","locator":"Lines 801-812","start_line":801,"end_line":812,"excerpt":"### curcumin-sulfasalazine-exposure\nSulfasalazine AUC increased 2.0-fold at the microdose and 3.2-fold at the therapeutic dose.\nCondition category: normal\nnutrient_topic: Curcumin research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: The human experiment measured more sulfasalazine in blood.\norganism: Human transporter/human participants; mouse claims separately scoped\ntissue_or_cell_type: Intestinal drug transport and plasma\nexperimental_model: Human pharmacokinetics, transporter vesicles and mouse knockout experiment\nlimitations: Small dose- and formulation-specific drug study. Transporter inference is supported by separate assays, not a universal effect on every BCRP substrate.\nexposure: Human: curcumin 2 g before sulfasalazine 100 micrograms or 2 g; eight participants. Mouse: 300-400 mg/kg curcumin\nevidence_span: {\"source_cache\": \"artifacts/curcumin-research/22300367.abstract.txt\", \"locator\": \"Primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"a8ec64e7dff4a52838fa067fdc9418ee3ebe768c4a4d53629bd84f9f0ffe67fe\", \"start_char\": 0, \"end_char\": 1713, \"text_sha256\": \"a8ec64e7dff4a52838fa067fdc9418ee3ebe768c4a4d53629bd84f9f0ffe67fe\"}\n[curcumin-p22300367] Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP. (2012). https://pubmed.ncbi.nlm.nih.gov/22300367/ DOI: 10.1111/j.1476-5381.2012.01887.x","model_system":"Human pharmacokinetics, transporter vesicles and mouse knockout experiment","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [curcumin-p22300367] Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP. (2012). https://pubmed.ncbi.nlm.nih.gov/22300367/ DOI: 10.1111/j.1476-5381.2012.01887.x","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"11d29ea9-3af1-5404-a68d-6f129e23edee","stable_key":"import-53d9b98d-e3a0-5416-bc88-adbe42a8cb1b","title":"Curcumin: metabolism, signaling and nutrient connections (2026-09-17)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"6eeda0e6e358e0b19f73f554f8c027cb08015aa49d92a77bde36e3fb3ea1a41c","revision_id":"32e73d69-5445-5ace-b25d-5a4d3787aea5","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}